Arca
Skip to content
Tools
Tools

PARC, PARE: Topoisomerase IV

Complex in Bacteria that 19 drugs act on.

  • Drugs that act on it: 19
  • Approved: 9
  • In phases 1 to 3: 10
  • Sponsors: 13

Who is on it, and how far along

Every drug ChEMBL records acting on PARC, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 19

Approved9

  • Moxifloxacin
  • Ciprofloxacin
  • Delafloxacin
  • Norfloxacin
  • Alatrofloxacin
  • Besifloxacin
  • Garenoxacin
  • Sparfloxacin
  • Trovafloxacin

Phase 36

  • Gepotidacin
  • Nadifloxacin
  • Nemonoxacin
  • Prulifloxacin
  • Sitafloxacin anhydrous
  • Zabofloxacin

Phase 24

  • Rifaquizinone
  • Pefloxacin
  • Acorafloxacin
  • Pradofloxacin

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Dong Wha Pharmaceutical Co. Ltd.15%
    • Furiex Pharmaceuticals, Inc15%
    • Iterum Therapeutics, International Limited15%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Topoisomerase IV inhibitor.
    MoxifloxacinBoxed warningApprovedBayerSmall moleculeInhibitor65
    CiprofloxacinBoxed warningApprovedIterum Therapeutics, International LimitedSmall moleculeInhibitor56
    DelafloxacinBoxed warningApprovedMelinta TherapeuticsSmall moleculeInhibitor1
    NorfloxacinBoxed warningApprovedMerck & Co. (MSD)Small moleculeInhibitor1
    AlatrofloxacinWithdrawnApprovedPfizerSmall moleculeInhibitor0
    BesifloxacinApprovedBausch & LombSmall moleculeInhibitor0
    GarenoxacinApproved—Small moleculeInhibitor0
    SparfloxacinApprovedViatrisSmall moleculeInhibitor0
    TrovafloxacinWithdrawn Boxed warningApprovedPfizerSmall moleculeInhibitor0
    GepotidacinPhase 3GSKSmall moleculeInhibitor3
    NadifloxacinPhase 3—Small moleculeInhibitor1
    NemonoxacinPhase 3TaiGen Biotechnology Co., Ltd.Small moleculeInhibitor1
    PrulifloxacinPhase 3Lee's PharmSmall moleculeInhibitor0
    Sitafloxacin anhydrousPhase 3—Small moleculeInhibitor0
    ZabofloxacinPhase 3Dong Wha Pharmaceutical Co. Ltd.Small moleculeInhibitor0
    RifaquizinonePhase 2TenNor Therapeutics (Suzhou)Small moleculeInhibitor2
    PefloxacinPhase 2—Small moleculeInhibitor1
    AcorafloxacinPhase 2Furiex Pharmaceuticals, IncSmall moleculeInhibitor0
    PradofloxacinPhase 2—Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 26 in all, from ClinicalTrials.gov.
    Randomized, Multicenter, Non-inferiority Trial Comparing the Efficacy of Fosfomycin Versus Fluoroquinolones or Cotrimoxazole as Oral Follow-up Treatment in Febrile Urinary Tract Infections in Men Caused by Susceptible EnterobacteriaCiprofloxacinPhase 3Not yet recruitingAssistance Publique - Hôpitaux de ParisNov 12, 2026
    A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy ParticipantsMoxifloxacinPhase 1RecruitingKyorin Pharmaceutical Co.,LtdNov 5, 2026
    Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese ParticipantsMoxifloxacinPhase 1RecruitingHaisco Pharmaceutical Group Co., Ltd.Nov 4, 2026
    Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate AcneNadifloxacinPhase 4RecruitingNishtar Medical UniversityNov 4, 2026
    Curcumin Extract Added to Ciprofloxacin for Typhoid Carriers Among Food Handlers of the Free Nutritious Meal ProgramCiprofloxacinPhase 2Not yet recruitingUniversitas Sebelas MaretOct 30, 2026
    Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated BrucellosisMoxifloxacinNot applicableNot yet recruitingThe First Affiliated Hospital of Shihezi UniversityOct 21, 2026
    All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular BrucellosisMoxifloxacinNot applicableNot yet recruitingThe First Affiliated Hospital of Shihezi UniversityOct 21, 2026
    A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult ParticipantsMoxifloxacinPhase 1RecruitingEpygenixOct 16, 2026
    Comparison of Postoperative Pain After Double Antibiotic Paste vs Calcium Hydroxide in Teeth With Symptomatic Apical PeriodontitisCiprofloxacinNot applicableRecruitingCollege of Physicians and Surgeons PakistanOct 9, 2026
    A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI ParticipantsRifaquizinonePhase 2RecruitingTenNor Therapeutics (Zhongshan) LimitedOct 5, 2026
    Efficacy and Safety of Second-Line Helicobacter Pylori EradicationMoxifloxacinNot applicableActive, not recruitingSeoul National University Bundang HospitalOct 2, 2026
    Prospective Registry of Exposure to Gepotidacin (PREG)Gepotidacin—RecruitingGlaxoSmithKlineSep 30, 2026
    Intracameral Levofloxacin Versus Moxifloxacin After Cataract SurgeryMoxifloxacinNot applicableNot yet recruitingAssiut UniversitySep 30, 2026
    Restrictive Versus Standard Antibiotic Treatment During CAR-T TherapyCiprofloxacinPhase 2Not yet recruitingZealand University HospitalSep 25, 2026
    Acetic Acid Ear Drops Versus 0.3 % Ciprofloxacin for Chronic Suppurative Otitis Media.CiprofloxacinNot applicableNot yet recruitingDow University of Health SciencesSep 22, 2026
    Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious ProcessesMoxifloxacinNot applicableNot yet recruitingNishtar Medical UniversitySep 9, 2026
    Population Pharmacokinetic Model of Rifampicin in Staphylococcal Osteoarticular InfectionsCiprofloxacinNot applicableRecruitingGroupe Hospitalier Diaconesses Croix Saint-SimonAug 26, 2026
    Drug-induced Crystalluria in Sulfamethoxazole, High Dose Ciprofloxacin and High Dose AmoxicillinCiprofloxacinNot applicableRecruitingUniversitair Ziekenhuis BrusselAug 19, 2026
    Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Periodontitis: A Randomized Controlled TrialCiprofloxacinNot applicableNot yet recruitingAll India Institute of Medical SciencesAug 13, 2026
    A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating WomenGepotidacinPhase 1RecruitingGlaxoSmithKlineJun 12, 2026
    Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections.Delafloxacin—Not yet recruitingIRCCS San RaffaeleFeb 23, 2026
    A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis AntibioticsGepotidacinPhase 1Not yet recruitingGlaxoSmithKlineJan 28, 2026
    Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review StudyNemonoxacin—Active, not recruitingNational Taiwan University HospitalMay 6, 2025
    A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI ParticipantsRifaquizinonePhase 1 / Phase 2RecruitingTenNor Therapeutics Inc.Mar 21, 2025
    Clinical Markers of Dysphagia in Cardiac Surgical PatientsPefloxacin—Active, not recruitingUniversity of FloridaMar 31, 2022
    Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial PeritonitisNorfloxacinPhase 3RecruitingTanta UniversityNov 13, 2019

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363076, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.